Angina Pectoris Drugs

Global Market Trajectory & Analytics

MCP10288

EXECUTIVE ENGAGEMENTS

POOL

5602
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

896
Interactions with Platform & by Email

PARTICIPANTS

168
Unique # Participated

VALIDATIONS

36
Responses Validated*

COMPANIES

46
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

66

PAGES

142

EDITION

9

PRICE

USD 4950

CODE

MCP10288


COMPETITIVE METRICS

COMPANY

D S N T

% *

Amgen, Inc.

Bayer AG

Eli Lilly and Company

Genmed Group Limited

Gilead Sciences, Inc.

GlaxoSmithKline PLC

Kynerion S.r.l.

Merck & Co., Inc.

Novartis International AG

Otsuka Pharmaceutical Co., Ltd.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Angina Pectoris Drugs estimated at US$10 Billion in the year 2020, is projected to reach a revised size of US$14.3 Billion by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027. Antiplatelet Agents, one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$4.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Beta-Adrenergic Blocking Agents segment is readjusted to a revised 5% CAGR for the next 7-year period.
The Angina Pectoris Drugs market in the U.S. is estimated at US$2.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
In the global Calcium Channel Blockers segment, USA, Canada, Japan, China and Europe will drive the 5.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.2 Billion in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.6 Billion by the year 2027.

SELECT PLAYERS

Amgen, Inc.; Bayer AG; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline PLC; Merck & Co., Inc.; Novartis AG; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sanofi SA

SEGMENTS

» Segment (Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors, Anti-Ischemic Agents)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Angina Pectoris Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Angina Pectoris Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Angina Pectoris Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Antiplatelet Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Antiplatelet Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Antiplatelet Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Beta-Adrenergic Blocking Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Beta-Adrenergic Blocking Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Beta-Adrenergic Blocking Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Short & Long Acting Nitroglycerines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Short & Long Acting Nitroglycerines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Short & Long Acting Nitroglycerines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Angiotensin-Converting Enzyme (ACE) inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Angiotensin-Converting Enzyme (ACE) inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Angiotensin-Converting Enzyme (ACE) inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Anti-Ischemic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-Ischemic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-Ischemic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Angina Pectoris Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Angina Pectoris Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Angina Pectoris Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Angina Pectoris Drugs by Segment - Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Angina Pectoris Drugs by Segment - Percentage Breakdown of Value Sales for Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) inhibitors and Anti-Ischemic Agents for the Years 2012, 2020 & 2027
Total Companies Profiled: 46

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com